Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys

 

  Braxton, a seven-time Grammy Award-winning singer, songwriter, actress, producer, and entrepreneur, will share her personal lupus journey to empower people with lupus and lupus nephritis to prioritize their kidney health as part of Aurinia's Get Uncomfortable campaign  

 

  The Get Uncomfortable campaign is designed to educate and motivate people living with lupus nephritis to protect their kidneys by going to the doctor and completing routine testing to help prevent irreversible kidney damage  

 

Toni Braxton, the award-winning singer, songwriter, actress, producer, and entrepreneur is speaking out about living with lupus and the importance of prioritizing kidney health. In partnership with Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical company committed to changing the trajectory of autoimmune disease, Braxton hopes to inspire people living with lupus nephritis a serious and common complication of lupus that can lead to permanent kidney damage or kidney failure to see their doctor regularly to complete routine testing and discuss kidney health and treatment options.

 

Braxton, who was diagnosed with lupus in 2008, will share her story about life with lupus and how she had to embrace uncomfortable moments to effectively manage her kidney health and prevent life-threatening complications.

 

"Getting routine urine tests and seeing a doctor regularly is so important because up to 30 percent of people with lupus who have kidney involvement will experience kidney failure," said Toni Braxton. "While peeing in a cup is never comfortable, it is so much better than a kidney transplant or dialysis. During the past 15 years, I've learned to prioritize my kidney care and to be a strong advocate for my health – and I'm speaking out now to encourage other women to do the same."

 

Braxton's partnership with Aurinia is part of the "Get Uncomfortable" campaign, which focuses on empowering people with lupus nephritis to make their kidney health a top priority. The campaign depicts highly relatable—although sometimes uncomfortable—situations involved in routine monitoring of lupus nephritis and highlights the importance of protecting the kidneys by staying ahead of irreversible kidney damage.

 

"As part of our ongoing commitment to raising awareness for lupus nephritis, we are thrilled to partner with Toni Braxton on the Get Uncomfortable campaign. Since launching in October 2022, the Get Uncomfortable campaign has reached thousands of patients with important information about routine urine testing and treatment options to support informed discussions with their healthcare team. Toni's relatable and authentic story about living with lupus will further inspire people living with lupus nephritis to better understand their health risks and take action to protect their kidneys before it's too late," said Peter Greenleaf, President and Chief Executive Officer of Aurinia.

 

Aurinia is committed to helping people to take charge of their lupus nephritis, which disproportionately impacts women of color. Black and Asian women are four times more likely to develop it, and Hispanic and Native American women are twice as likely to develop it compared to non-Hispanic White women. The risk of death is three times greater for people with lupus nephritis than for other people with lupus without kidney involvement. By encouraging doctor visits and routine monitoring through urine and blood tests, Aurinia hopes to help people with lupus nephritis avoid further permanent kidney damage and kidney failure.

 

To learn more visit www.getuncomfortable.com . Toni Braxton will also be sharing information about the Get Uncomfortable campaign on her social media channels.

 

  About Lupus Nephritis  

 

Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE), a chronic and complex autoimmune disease. About 200,000-300,000 people live with SLE in the U.S. and about one-third of these people are diagnosed with lupus nephritis at the time of their SLE diagnosis. About 50 percent of all people with SLE may develop lupus nephritis. If poorly controlled, LN can lead to permanent and irreversible tissue damage within the kidney. Black and Asian individuals with SLE are four times more likely to develop LN and individuals of Hispanic ancestry are approximately twice as likely to develop the disease when compared with White people with SLE. Black and Hispanic individuals with SLE also tend to develop LN earlier and have poorer outcomes when compared to White people with SLE.

 

  About Aurinia  

 

 Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company's head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

 

  

  

  Corporate/Media:  
Andrea Christopher
Corporate Communications/Corporate Affairs, Aurinia
achristopher@auriniapharma.com  

Investors:  
Aurinia@westwicke.com  

 

News Provided by Business Wire via QuoteMedia

AUPH
The Conversation (0)
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees

 

 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission (SEC).

 

Under U.S. federal securities laws, equity awards issued as employee compensation must be registered under the Securities Act of 1933, as amended, via an S-8 registration statement or qualify for an exemption from registration. This Form S-8 registers previously issued and disclosed stock options and restricted stock units (RSUs) that were granted as inducement awards to employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Announces 2023 Annual General Meeting Results

Aurinia Announces 2023 Annual General Meeting Results

 

 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") today announced voting results for its annual general meeting (the "Meeting") of shareholders held on May 17, 2023.

 

Shareholders re-elected six of eight incumbent directors to the Board of Directors (the "Board"). Two directors, George Milne and Joseph ("Jay") Hagan, while elected under applicable corporate law, received less than majority support and have submitted their resignations for consideration by the Board, pursuant to the Company's Majority Voting Policy. In accordance with the policy, the Board intends to act expeditiously in respect to the submitted resignations to ensure an orderly transition.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS®  AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

 

  First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS ® (voclosporin)  

 

  Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms from baseline to follow-up  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results

 

  $34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year  

 

  Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS  

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS®  For Adults with Active Lupus Nephritis

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® For Adults with Active Lupus Nephritis

 

 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including mixed class III/V and IV/V) 1 , when provided in combination with mycophenolate mofetil (MMF).

 

The NICE recommendation applies to England and Wales and follows the recent Medicines and Healthcare Products Regulatory Agency (MHRA) authorization of voclosporin licensed in Great Britain for the treatment of active LN in adult patients.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less
Amplia Therapeutics

Accent Trial Data Demonstrates that Narmafotinib + Chemotherapy Combination Superior to Chemotherapy Alone

Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have now been recorded in the trial, a level of response sufficient to demonstrate that the combination of narmafotinib and chemotherapy is superior to chemotherapy alone.
Keep reading...Show less

Latest Press Releases

Related News

×